Teva has set out more details of how it plans to improve its profit margins in the wake of an extensive restructuring of the business, as the firm has reported a mixed impact from the COVID-19 pandemic in the first quarter of 2020.
Having at the end of 2019 celebrated the completion of a long-term restructuring plan – with measures that included cutting...




